J. Carboni

发表

A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation

P. Sorensen, C. Chow, G. Morin, 2012, Oncogene.

Localization of villin, a cytoskeletal protein specific to microvilli, in human ileum and colon and in colonic neoplasms.

A B West, K W Barwick, A. West, 1988, Gastroenterology.

Identification of CD18 as a novel Taxol binding/signaling protein in murine macrophage membranes

T. Mayadas, D. Golenbock, S. Vogel, 1999 .

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

H. Masoudi, R. Nicholson, S. Dunn, 2008, Cancer research.

Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase

M. Barbacid, S. Robinson, B. Seizinger, 1995 .

LPS and Taxol Activate Lyn Kinase Autophosphorylation in Lpsn, but Not in Lpsd, Macrophages

A. Burkhardt, S. Vogel, J. Carboni, 1995, Molecular medicine.

Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol).

C. Fairchild, T. Lindel, P. Jensen, 1998, Cancer research.

Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.

M. Gottardis, R. Attar, A. Greer, 2007, Bioorganic & medicinal chemistry letters.

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.

Chiehying Y Chang, M. Gottardis, R. Attar, 2005, Journal of medicinal chemistry.

Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).

D. Langley, J. Sack, Chiehying Y Chang, 2007, Bioorganic & medicinal chemistry letters.

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.

D. Langley, M. Gottardis, R. Attar, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

G. Trainor, A. Mathur, D. Langley, 2009, Journal of medicinal chemistry.

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.

G. Trainor, M. Gottardis, A. Greer, 2010, Bioorganic & medicinal chemistry letters.

Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis.

L. Shantz, D. Bol, D. Feith, 2005, Cancer research.

IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Fei Huang, Dharmesh M. Patel, Han Chang, 2014, Molecular Cancer Therapeutics.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

F. Huang, P. Haluska, M. Gottardis, 2011, Cancer research.

Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.

P. Ross-Macdonald, H. de Silva, Isaac Neuhaus, 2012, Bioorganic & Medicinal Chemistry.

ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.

P. Sorensen, N. Melnyk, C. Tognon, 2011, Cancer research.

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

D. Leroith, A. Rowzee, T. Wood, 2010, Cancer research.

The EGF/TGFα response element within the TGFα promoter consists of a multi-complex regulatory element

W. Scovell, M. Brattain, G. Howell, 1999, Oncogene.

Regulation of Transforming Growth Factor α Expression in a Growth Factor-Independent Cell Line

J. Willson, B. Ziober, M. Brattain, 1998, Molecular and Cellular Biology.

Aberrant Regulation of Transforming Growth Factor-α during the Establishment of Growth Arrest and Quiescence of Growth Factor Independent Cells*

J. Willson, B. Ziober, M. Brattain, 1998, The Journal of Biological Chemistry.

SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.

S. P. Seitz, M. Gottardis, R. Attar, 2010, Bioorganic & medicinal chemistry letters.

Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.

A. Wolff, D. Nuyten, F. Huang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The dual IGF-1 R / InsR inhibitor , BMS-754807 , demonstrates synergy in combination with hormonal agents in vitro and enhances in vivo activity in an estrogen-dependent breast cancer model

F. Huang, P. Haluska, M. Gottardis, 2011 .

Therapeutics , Targets , and Chemical Biology Dual IGF-1 R / InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

F. Huang, P. Haluska, M. Gottardis, 2011 .

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.

Chiehying Y Chang, M. Gottardis, R. Attar, 2007, Bioorganic & medicinal chemistry letters.

Localization of actin in Chlamydomonas using antiactin and NBD-phallacidin.

J. Condeelis, P. Detmers, J. Carboni, 1985, Cell motility.

Macrophages: Identification of Murine CD18 Identify Unique Cellular Targets in Murine Use of a Photoactivatable Taxol Analogue to

T. Mayadas, D. Golenbock, S. Vogel, 1999 .

Assembly of the intestinal brush border: appearance and redistribution of microvillar core proteins in developing chick enterocytes

M. Mooseker, J. Carboni, T. Shibayama, 1987, The Journal of cell biology.

Transforming Growth Factor-ÃŸlInduces Activity and Transforming Growth Factor-a Secretion in the Human Colon Adenocarcinoma Cell Line FET1

J. Carboni, Michael, M. Lynch, 2006 .

Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor

Xia Han, F. Huang, L. Helman, 2007 .

Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.

M. Barbacid, C. Der, B. Seizinger, 1995, Oncogene.

Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.

M. Barbacid, C. Der, B. Seizinger, 1995, Oncogene.

Antigen-induced increase in migration of large cortical thymocytes (regulatory cells?) to the marginal zone and red pulp of the spleen.

H. Durkin, J. Carboni, B. Waksman, 1978, Journal of immunology.

Advances in Brief Eleutherobin , a Novel Cytotoxic Agent That Induces Tubulin Polymerization , Is Similar to Paclitaxel ( TaxolÂ ® ) 1

Arthur, Laurie, J. Wasserman, 2006 .

Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.

M. Barbacid, B. Seizinger, M. Young, 1995, Journal of medicinal chemistry.

Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Y. Asmann, F. Huang, K. Flatten, 2011, Molecular Cancer Therapeutics.

Blocking IGF1R signaling in ETV6-NTRK3 breast cancer

N. Melnyk, C. Tognon, Valentina Evdokimova, 2010 .

Synthesis of a photoaffinity analog of taxol as an approach to identify the taxol binding site on microtubules.

I. Ringel, S. Horwitz, J. Carboni, 1993, Journal of medicinal chemistry.

Characterization of intestinal brush border cytoskeletal proteins of normal and neoplastic human epithelial cells. A comparison with the avian brush border.

A. West, C. Howe, M. Mooseker, 1987, The American journal of pathology.

Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry.

S. Hill, K. Volk, M. Lee, 1998, Rapid communications in mass spectrometry : RCM.

Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.

B. Seizinger, J. Hunt, V. Manne, 1996, Journal of medicinal chemistry.

Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

M. Barbacid, B. Seizinger, J. Hunt, 1996, Journal of medicinal chemistry.

Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.

J. Sack, Chiehying Y Chang, A. Greer, 2010, Bioorganic & medicinal chemistry letters.

Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.

D. Langley, M. Gottardis, R. Attar, 2008, Bioorganic & medicinal chemistry letters.

Constitutively Active Insulin-Like Growth Factor I Receptor Tumor Development by Transgenic Expression of a

Adrian V. Lee, F. Lee, D. Bol, 2005 .

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activ

Zheng Yang, Sean Kim, Praveen Balimane, 2008, Journal of medicinal chemistry.

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

C. Conover, F. Lee, D. Loegering, 2006, Cancer research.

Electron-microscopic study of the apical region of the toad bladder epithelial cell.

R. M. Hays, J. Condeelis, C. Robertson, 1984, The American journal of physiology.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Zheng Yang, G. Trainor, F. Lee, 2009, Molecular Cancer Therapeutics.

BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells

Adrian V. Lee, B. Litzenburger, C. Fairchild, 2009, Clinical Cancer Research.

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

A. Trumpp, J. Aster, A. Weng, 2011, The Journal of experimental medicine.

Properties of the 120,000- and 95,000-dalton actin-binding proteins from Dictyostelium discoideum and their possible functions in assembling the cytoplasmic matrix

J. Condeelis, S. Ogihara, M. Vahey, 1984, The Journal of cell biology.

Ultrastructural localization of cytoskeletal proteins in Dictyostelium amoebae.

J. Condeelis, A. Hall, H. Bennett, 1987, Methods in cell biology.

Ligand-induced changes in the location of actin, myosin, 95K (alpha- actinin), and 120K protein in amebae of Dictyostelium discoideum

J. Condeelis, J. Carboni, Joan M. Carboni, 1985, The Journal of cell biology.

Ligand-induced Changes in the Location of Actin, Myosin, 95K (c -Actinin), and 120K in Amebae of Dictyostelium discoideum Protein

J. Condeelis, J. Carboni, 1985 .

Electron microscopic localization of myosin II and ABP-120 in the cortical actin matrix of Dictyostelium amoebae using IgG-gold conjugates.

J. Condeelis, S. Ogihara, J. Carboni, 1988, Developmental genetics.

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

A. Yasmeen, M. Pollak, M. Gottardis, 2009, Gynecologic oncology.

Partial deduced sequence of the 110-kD-calmodulin complex of the avian intestinal microvillus shows that this mechanoenzyme is a member of the myosin I family

M. Arpin, M. Mooseker, D. Louvard, 1989, The Journal of cell biology.

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

Xia Han, F. Huang, F. Lee, 2009, Cancer research.

Rationale for Combining with EGFR / HER 2 Inhibitors Growth Factor-1 Receptor Inhibitor ( BMS-536924 ) and The Mechanisms of Differential Sensitivity to an Insulin-like Updated

Xia Han, F. Huang, F. Lee, 2008 .

Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail

Adrian V. Lee, B. Litzenburger, X. Cui, 2007, Molecular and Cellular Biology.

Transforming growth factor-beta 1 induces transforming growth factor-alpha promoter activity and transforming growth factor-alpha secretion in the human colon adenocarcinoma cell line FET.

P. F. Lin, M. Brattain, L. Pelosi, 1993, Cancer research.

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

C. Erlichman, P. Haluska, M. Gottardis, 2008, Molecular Cancer Therapeutics.

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy

Adrian V. Lee, S. Hilsenbeck, B. Litzenburger, 2010, Clinical Cancer Research.

NOVEL C-4 PACLITAXEL (TAXOL) ANALOGS : POTENT ANTITUMOR AGENTS

Jianmei Wei, C. Fairchild, J. Kadow, 1995 .

IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

A. Weng, Christopher R Jenkins, V. Giambra, 2012, Experimental hematology.

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

R. Lloyd, P. Haluska, M. Ames, 2010, Endocrine-related cancer.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

D. Loegering, B. Smith, J. Karp, 2009, Cancer research.

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

S. Avnet, M. Salerno, N. Baldini, 2009, Cancer research.

Structural and immunological characterization of the myosin-like 110-kD subunit of the intestinal microvillar 110K-calmodulin complex: evidence for discrete myosin head and calmodulin-binding domains

T. Pollard, D. Kaiser, M. Mooseker, 1988, The Journal of cell biology.

Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression.

T. Mayadas, D. Golenbock, S. Vogel, 1999, Journal of immunology.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Adrian V. Lee, F. Lee, D. Bol, 2005, Cancer research.

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

J. Fargnoli, F. Huang, M. Gottardis, 2010, Cancer research.

Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in Cancer

F. Huang, J. Carboni, M. Wittman, 2012 .

IRS 2 Copy Number Gain , KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1 R / IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Dharmesh M. Patel, Han Chang, F. Huang, 2015 .

Copy Number Gain , KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1 R / IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Dharmesh M. Patel, Han Chang, F. Huang, 2015 .

Eleutherobin, a New Cytotoxin that Mimics Paclitaxel (Taxol) by Stabilizing Microtubules.

C. Fairchild, T. Lindel, P. Jensen, 1997 .

Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

C. Logothetis, M. Gottardis, G. Gallick, 2012, PloS one.

Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

P. Sorensen, S. Aparicio, S. McKinney, 2010, Cancer research.

B cells in the appendix and other lymphoid organs of the rabbit: complement receptor lymphocytes.

J. Carboni, B. Waksman, C. Calkins, 1975, Journal of immunology.

Novel C-4 Paclitaxel (Taxol) Analogues: Potent Antitumor Agents

Jianmei Wei, C. Fairchild, J. Kadow, 1996 .

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

F. Huang, M. Gottardis, R. Attar, 2010, Endocrinology.

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

M. Pollak, M. Gottardis, E. Birman, 2011, Endocrine-related cancer.

Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins.

J. Carboni, M. Tepper, C. Singh, 1993, Journal of the National Cancer Institute. Monographs.

Taxol-Induced Gene Expression as a Major Taxol-Binding Protein and a Role Macrophages : Identification of Murine CD 18 Identify Unique Cellular Targets in Murine Use of a Photoactivatable Taxol Analogue to

T. Mayadas, D. Golenbock, S. Vogel, 1999 .

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

S. Weroha, P. Haluska, M. Gottardis, 2012, Clinical Cancer Research.

Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo.

F. Huang, P. Haluska, M. Gottardis, 2009 .

Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Y. Asmann, C. T. Eyck, C. Erlichman, 2009 .

CD14 dependent and independent signaling pathways in murine macrophages from normal and CD14 "knockout" (CD14KO) mice stimulated with LPS or taxol.

S. Goyert, S. Vogel, G. Detore, 1998, Progress in clinical and biological research.

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy

Adrian V. Lee, S. Hilsenbeck, B. Litzenburger, 2010, Clinical Cancer Research.

Bms-536924 Reverses Igf-ir-induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of Mcf7 Cells Cancer Therapy: Preclinical

B. Litzenburger, M. Gottardis, I. Kuiatse, 2022 .

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer.

Jeffrey T. Chang, Adrian V. Lee, B. Litzenburger, 2009 .

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

D. Leroith, A. Rowzee, T. Wood, 2010, Cancer research.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

F. Huang, P. Haluska, M. Gottardis, 2011, Cancer research.

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

J. Fargnoli, F. Huang, M. Gottardis, 2010, Cancer research.